Study design
lung cancer, renal or coagulation
LUNG CANCER, SECONDARY, COMPLICATIONS
The study protocol of this single-center RCT was approved by our center’s Institutional Review Board. All participants gave written, informed-consent. In addition, this RCT was listed within ClinicalTrials.gov (NCT04217655).From June 2020 to December 2020, consecutive eligible patients with PNs were randomly assigned into low-dose and standard-dose groups. Table Scanning parameters between 2 groupsInclusion criteria: (a) clinical cases with PNs, detected on CT; (b) solid PNs; (c) PNs > 8 mm; (d) PNs having intermediate-high risk for lung cancer, depending upon clinical/radiology-based characteristics [Exclusion criteria: (a) patients who underwent CT-guided biopsy previously; (b) PNs which were stable in size for at least 1 year; (c) PNs that decreased in size during follow-up; (d) clinical cases having a history of intense cardiac, pulmonary, renal or coagulation dysfunctional conditions; and (e) patients who refused to join this RCT.The primary endpoint of this RCT was diagnostic accuracy. The secondary endpoints included technical success, diagnostic yield, operation time, radiation dose, and biopsy-related complications.